AUROBINDO PHARMA LIMITED D&B D-U-N-S® No 65-008-2092

Company Ranking
Net Net
Income
Aurobindo has a major presence in custom synthesis and generic formulations Profit Worth
194 303 135
History portfolio comprises therapeutic areas such Company Details
PVR Reddy and K N Reddy founded as antibiotics, anti-retrovirals, CVS, CNS, Registered office
Aurobindo Pharma Ltd (Aurobindo) in 1986. gastroenterologicals and anti-allergics and Plot No 2, Maitri Vihar
65 APIs in non-antibiotics and 55 APIs in Ameerpet
The company commenced operations in 1989
antibiotic segments. Aurobindo exports to Hyderabad - 500038
with a single unit manufacturing semi-synthetic AP
penicillin. The company made an IPO in over 100 countries. It has 10 subsidiaries and
three JVs. In FY05, the company filed 64 DMFs Chairperson
1995. In Apr 2000, Aurobindo amalgamated PVR Reddy
Sri Chakra Remedies Ltd with itself. In 2003, and 25 ANDAs. APIs contributed to 59% of its
revenue. In 2005, Aurobindo purchased a sterile Managing Director
it set up Citadel Aurobindo Biotech Ltd, in K N Reddy
a JV with Citadel Fine Pharmaceuticals Ltd plant of Dee Pharma at Bhiwadi, Rajasthan, for
Directors
and transferred its ethical allopathic branded Rs 38 mn.
M Sivakumaran, BSP Reddy, L Srinivas,
formulations business to this JV. I Sathyamurthy, V S Janardhanam,
The Year in Review S B Singh, K A Balasubramanian, K S Butalia,
Operations For the year to Mar 31, 2005, total income S Lanka, V S Janardhanan, S B Singh
decreased to Rs 11 bn, down 14.1% over the Company Secretary
Aurobindo deals in APIs, intermediates,
previous year’s figure. Net profit decreased B A Reddy
and specialty generic formulations.
72.4% to Rs 350.8 mn. Bankers
It has manufacturing facilities in India, US, AB, Canara, Exim, HDFC Bank,
Brazil and China. The company operates ICICI Bank, SCB, SBH, SBI
through four divisions: Indus (focusing on gastro As per unaudited results for the nine months
Auditors
respiratory, infection and pain), Argus (focusing ended Dec 31, 2005, the company recorded S R Batliboi & Co
on cardiology and diabetology), Imunus an income of Rs 10.3 bn and a net profit of
(focusing on HIV/AIDS) and Genus Rs 318.4 mn as compared with an income of
(focuses branded speciality generic Rs 8.8 bn and a net profit of Rs 311.7 mn in the
formulations). The company’s product corresponding period previous year.